Modality
Bispecific Ab
MOA
PI3Ki
Target
JAK1
Pathway
Tau
Fabry
Development Pipeline
Preclinical
Dec 2019
→ Nov 2031
PreclinicalCurrent
NCT06706472
1,251 pts·Fabry
2019-12→2031-11·Recruiting
NCT08740738
812 pts·Fabry
2024-07→2025-11·Recruiting
2,063 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-284mo agoInterim· Fabry
2031-11-175.6y awayInterim· Fabry
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Recruit…
Preclinical
Recruit…
Catalysts
Interim
2025-11-28 · 4mo ago
Fabry
Interim
2031-11-17 · 5.6y away
Fabry
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06706472 | Preclinical | Fabry | Recruiting | 1251 | PFS |
| NCT08740738 | Preclinical | Fabry | Recruiting | 812 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 |